Interferon Beta 1a | List of Frontiers open access articles

Original Research

Published on 28 Nov 2023

Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study

in Multiple Sclerosis and Neuroimmunology

Raed Al-Roughani
Magd Zakaria
Edward J. Cupler
Karim Taha

Frontiers in Neurology

doi 10.3389/fneur.2023.1257455

2,414 views
1 citation

Original Research

Accepted on 04 Feb 2026

Evaluating Rational Use of Disease-Modifying Therapies for Multiple Sclerosis Using Claims Data

in Health Policy and Management

Xiang Wang
Fei-li Zhao
David Newby
Shuchuen Li

Frontiers in Health Services

138 views

Brief Research Report

Accepted on 17 Feb 2026

Reduced Peripheral Serotonin Levels in Women with Multiple Sclerosis: Associations with Underweight Status, Treatment Duration, and Use of Interferon Beta 1a

in Cellular Neuropathology

Gilberto Pérez-Sánchez
León Arturo Aguilar Gómez
Giselle Berenice Vela Sancho
Salomón Jacinto-Gutiérrez
Enrique Becerril-Villanueva
Samantha Alvarez Herrera
Luis Alberto Vallejo-Castillo
Mario Alberto Mireles-Ramírez
María Paulina Reyes Mata
Jose de Jesus Guerrero-Garcia

Frontiers in Cellular Neuroscience

Original Research

Published on 22 Jul 2021

Effectiveness, Healthcare Resource Utilization and Adherence to Subcutaneous Interferon Beta-1a According to Age in Patients With Multiple Sclerosis: A Cohort Study Using a US Claims Database

in Multiple Sclerosis and Neuroimmunology

Arthur Allignol
Emmanuelle Boutmy
Meritxell Sabidó Espin
Kurt Marhardt
Patrick Vermersch

Frontiers in Neurology

doi 10.3389/fneur.2021.676585

3,381 views
3 citations

Original Research

Published on 02 Sep 2020

Clinical Parameters to Predict Future Clinical Disease Activity After Treatment Change to Higher-Dose Subcutaneous Interferon Beta-1a From Other Platform Injectables in Patients With Relapsing-Remitting Multiple Sclerosis

in Multiple Sclerosis and Neuroimmunology

Martina Novotna
Ales Tvaroh
Jan Mares

Frontiers in Neurology

doi 10.3389/fneur.2020.00944

2,577 views

Case Report

Published on 25 Feb 2025

Case Report: Long-term suppression of relapses by dimethyl fumarate in a relapsing pediatric patient with myelin oligodendrocyte glycoprotein antibody–associated disease manifesting as acute disseminated encephalomyelitis, unilateral optic neuritis, and seizure episodes

in Multiple Sclerosis and Neuroimmunology

Masayuki Tahara
Tomonari Awaya
Keisuke Saito
Hideyuki Sawada

Frontiers in Immunology

doi 10.3389/fimmu.2025.1551379

2,854 views

Review

Published on 22 Mar 2019

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings

in Multiple Sclerosis and Neuroimmunology

Krista Barclay
Robert Carruthers
Anthony Traboulsee
Ann D. Bass
Christopher LaGanke
Antonio Bertolotto
Aaron Boster
Elisabeth G. Celius
Jérôme de Seze
Dionisio Dela Cruz

Frontiers in Neurology

doi 10.3389/fneur.2019.00253

12,798 views
23 citations

Original Research

Published on 12 Jan 2021

Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS

in Multiple Sclerosis and Neuroimmunology

Zbyšek Pavelek
Lukáš Sobíšek
Jana Šarláková
Pavel Potužník
Marek Peterka
Ivana Štětkárová
Pavel Štourač
Jan Mareš
Pavel Hradílek
Radek Ampapa

Frontiers in Neurology

doi 10.3389/fneur.2020.593527

4,045 views
4 citations

Original Research

Published on 24 Aug 2022

A nurse-led, telephone-based patient support program for improving adherence in patients with relapsing-remitting multiple sclerosis using interferon beta-1a: Lessons from a consumer-based survey on adveva® PSP

in Psychology for Clinical Settings

Serena Barello
Damiano Paolicelli
Roberto Bergamaschi
Salvatore Cottone
Alessandra D'Amico
Viviana Annibali
Andrea Paolillo
Caterina Bosio
Valentina Panetta
Guendalina Graffigna

Frontiers in Psychology

doi 10.3389/fpsyg.2022.965229

5,355 views
3 citations

Original Research

Published on 08 Jan 2026

Drug-induced peripheral nerve palsy: a real-world study based on FAERS data from 2004 to the third quarter of 2024

in Pharmacoepidemiology

Yingjie Li
Xueliang Yi
Nengwei Yu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1691263

885 views

Original Research

Published on 27 Mar 2025

Drug-induced kidney stones: a real-world pharmacovigilance study using the FDA adverse event reporting system database

in Renal Pharmacology

Pan Ding
Qinghua Luo
Leihua Cao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1511115

8,534 views
3 citations

Articles

Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study

Evaluating Rational Use of Disease-Modifying Therapies for Multiple Sclerosis Using Claims Data

Reduced Peripheral Serotonin Levels in Women with Multiple Sclerosis: Associations with Underweight Status, Treatment Duration, and Use of Interferon Beta 1a

Effectiveness, Healthcare Resource Utilization and Adherence to Subcutaneous Interferon Beta-1a According to Age in Patients With Multiple Sclerosis: A Cohort Study Using a US Claims Database

Clinical Parameters to Predict Future Clinical Disease Activity After Treatment Change to Higher-Dose Subcutaneous Interferon Beta-1a From Other Platform Injectables in Patients With Relapsing-Remitting Multiple Sclerosis

Case Report: Long-term suppression of relapses by dimethyl fumarate in a relapsing pediatric patient with myelin oligodendrocyte glycoprotein antibody–associated disease manifesting as acute disseminated encephalomyelitis, unilateral optic neuritis, and seizure episodes

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings

Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS

A nurse-led, telephone-based patient support program for improving adherence in patients with relapsing-remitting multiple sclerosis using interferon beta-1a: Lessons from a consumer-based survey on adveva® PSP

Drug-induced peripheral nerve palsy: a real-world study based on FAERS data from 2004 to the third quarter of 2024

Drug-induced kidney stones: a real-world pharmacovigilance study using the FDA adverse event reporting system database